The Yield

In addition to news and dividend information, on this episode, I cover my Low Yield portfolio.

It was a volatile week with the markets ending on an up note. All the markets were down overall for the week. Much of the downturn seemed related to the news cycle where inflation was rearing its ugly head and the gas pipeline operation stoppage. This week was another fine example of why I don’t buy for stock price but for dividend yield.

Wall Street Journal reports on inflation… again

WSJ searching for the pin that will pop the current economic bubble

Consumer prices rising a result of government COVID-19 response

Large U.S. banks poised to loosen requirements to get credit cards

Johnson & Johnson (JNJ): Norway should exclude the COVID-19 vaccines made by AstraZeneca and Johnson & Johnson from its inoculation programme due to a risk of rare but harmful side-effects, a government-appointed commission said on Monday. However, those who volunteer to take either vaccine should be allowed to do so, it said, stressing the importance of dispelling any vaccine hesitancy. https://www.reuters.com/world/europe/norway-should-exclude-jj-astrazeneca-covid-vaccination-scheme-says-commission-2021-05-10/Germany is lifting the prioritisation for giving Johnson & Johnson’s COVID-19 vaccine, Health Minister Jens Spahn said on Monday, adding that any adult who wants it will be able to receive the shot on a doctor’s advice. https://finance.yahoo.com/news/germany-lift-prioritisation-j-j-080939495.htmlThe U.S. Centers for Disease Control and Prevention said on Wednesday it had found more cases of potentially life-threatening blood clotting among people who received the Johnson & Johnson COVID-19 vaccine and sees a “plausible causal association.” The CDC said in a presentation the agency has now identified 28 cases of thrombosis with thrombocytopenia syndrome (TTS) among the more than 8.7 million people who had received the J&J vaccine. https://www.msn.com/en-us/health/medical/update-2-us-cdc-finds-more-clotting-cases-after-j-j-vaccine-sees-causal-link/ar-BB1gF6tEFriday J&J announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company’s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S, is being donated to the WHO by Janssen for the purposes of the early access clinical program. Johnson & Johnson also announced that its Ebola vaccine regimen has received Prequalification from the WHO, which will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus. https://www.jnj.com/johnson-johnson-joins-world-health-organization-in-efforts-to-prevent-spread-of-ebola-in-west-africa

Other vaccine news: In interviews with Reuters, more than a dozen influential infectious disease and vaccine development experts said there is growing evidence that a firs...